Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma

Clinical Cancer Research

Volumn 19, Issue 5, 2013, Pages 1094-1105

  Wik, Elisabeth ^a,b   Ræder, Maria B ^a,b   Krakstad, Camilla ^a,b   Trovik, Jone ^a,b   Birkeland, Even ^a,b   Hoivik, Erling A ^a,b   Mjos, Siv ^b   Werner, Henrica M J ^a,b   Mannelqvist, Monica ^b   Stefansson, Ingunn M ^a,b   Oyan, Anne M ^a,b   Kalland, Karl H ^a,b   Akslen, Lars A ^a,b   Salvesen, Helga B ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; GENOMIC DNA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SONIC HEDGEHOG PROTEIN; STATHMIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; WNT PROTEIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; ENDOMETRIUM CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; ESR1 GENE; FOLLOW UP; GENE ACTIVATION; GENE AMPLIFICATION; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECEPTOR GENE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

AGED; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR ALPHA; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84874852214     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3039     Document Type: Article

References (52)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005;55: 74-108.
2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005;366: 491-505.
3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15: 10-7.
4. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 2012;13:e353-61.
5. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 2008;199: 543 e1-7.
6. Jongen V, Briet J, de Jong R, ten Hoor K, Boezen M, van der Zee A, et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 2009;112: 537-42.
7. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007; 17: 964-78.
8. Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 2010;12:CD007926.
9. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119: 1420-8.
10. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139: 871-90.
11. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009;119: 1429-37.
12. Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ. Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax 2009;64: 1082-9.
13. Micalizzi DS, Ford HL. Epithelial-mesenchymal transition in development and cancer. Future Oncol 2009;5: 1129-43.
14. MellLK,Meyer JJ, TretiakovaM,KhramtsovA,GongC,YamadaSD,etal. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res 2004;10: 5546-53.
15. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004;22: 1242-52.
16. Mannelqvist M, Stefansson IM, Bredholt G, Hellem Bo T, Oyan AM, Jonassen I, et al. Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. Am J Pathol 2011; 178: 861-71.
17. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010;101: 293-9.
18. Krasnapolski MA, Todaro LB, de Kier Joffe EB. Is the epithelial- tomesenchymal transition clinically relevant for the cancer patient? Curr Pharm Biotechnol 2011;12: 1891-9.
19. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 2009;106: 4834-9.
20. Stefansson IM, Salvesen HB, Immervoll H, Akslen LA. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 2004;44: 472-9.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995;57: 11.
22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad SciU S A 2005;102: 15545-50.
23. Efron B, Tibshirani R.Ontesting the significance of gene sets. Ann Appl Stat 2007;1: 22.
24. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313: 1929-35.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(delta delta C(T)) method. Methods 2001;25: 402-8.
26. Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res 2005;65: 10938-45.
27. Benjamin JM, Nelson WJ. Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis. Semin Cancer Biol 2008;18: 53-64.
28. Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, StaffAC, et al. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 2011;17: 3368-77.
29. Birkeland E, Wik E, Trovik J, Werner HM, Mjos S, Kusanmano K, et al. KRAS gene amplification but not mutation associates with aggressive and metastatic endometrial cancer. Br J Cancer 2012;107: 1997-2004.
30. Kutz SM, Higgins CE, Samarakoon R, Higgins SP, Allen RR, Qi L, et al. TGF-beta 1-induced PAI-1 expression is E box/USF-dependent and requires EGFR signaling. Exp Cell Res 2006;312: 1093-105.
31. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415: 436-42.
32. Kenny PA, Enver T, Ashworth A. Receptor and secreted targets of Wnt- 1/beta-catenin signalling in mouse mammary epithelial cells. BMC Cancer 2005;5: 3.
33. Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem2001;276: 17058-62.
34. Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003;113: 207-19.
35. Nagai MA, Brentani MM. Gene expression profiles in breast cancer to identify estrogen receptor target genes. Mini Rev Med Chem 2008; 8: 448-54.
36. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta 2012;1826: 297-311.
37. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007;104: 7564-9.
38. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010;2: 26ra5.
39. Creasman WT, McCarty KS Sr, Barton TK, McCarty KS Jr. Clinical correlates of estrogen- and progesterone-binding proteins in human endometrial adenocarcinoma. Obstet Gynecol 1980;55: 363-70.
40. Iversen OE, Utaaker E, Skaarland E. DNA ploidy and steroid receptors as predictors of disease course in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 1988;67: 531-7.
41. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17: 1736-44.
42. Blechschmidt K, Kremmer E, Hollweck R, Mylonas I, Hofler H, Kremer M, et al. The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn Mol Pathol 2007;16: 222-8.
43. Dhasarathy A, Kajita M, Wade PA. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol 2007;21: 2907-18.
44. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol 2009;5: 1145-68.
45. Muinelo-Romay L, Colas E, Barbazan J, Alonso-Alconada L, Alonso- Nocelo M, Bouso M, et al. High-risk endometrial carcinoma profiling identifies TGF-beta1 as a key factor in the initiation of tumor invasion. Mol Cancer Ther 2011;10: 1357-66.
46. Tang D, Xu S, Zhang Q, Zhao W. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol 2012;29: 526-33.
47. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from Ecadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007;13: 7003-11.
48. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29: 3278-85.
49. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011;8: 261-71.
50. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21: 99-102.
51. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28: 1075-83.
52. Konopka B, Janiec-Jankowska A, Kwiatkowska E, Najmola U, Bidzinski M, Olszewski W, et al. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. Hum Pathol 2011;42: 1710-9.